Clinical Studies In a randomized controlled trial from 2004 to 2009, 58 AML patients aged 60–88 years were randomly assigned to receive chemotherapy (control group; n=28) or it plus HLA-mismatched G-CSF–mobilized donor peripheral blood stem cell (G-PBSC) (G-PBSC group/ Microtransplantation; n = 30). The complete remission rate was significantly higher in the G-PBSC group than in the control group (80.0\% vs 42.8\%); The median recovery times of neutrophils and platelets were 11 days and 14.5 days, respectively, in the G-PBSC group and 16 days and 20 days, respectively, in the control group after chemotherapy; The 2-year probability of disease-free survival (DFS) was significantly higher in the G-PBSC group than in the control group (38.9\% vs URL No graft-versus-host disease was observed in any URL Persistent donor microchimerism was successfully detected in all of the 4 female URL In another long-term research from 2004-2011, 101 patients with AML-CR1 (9 to 65 years old) received Microtransplantation regimen. The 6-year leukemia-free survival (LFS) and overall survival (OS) rates were 84.4\% and 89.5\%, respectively, in the low-risk group, which were similar to the rates in the intermediate-risk group (59.2\% and 65.2\%, respectively); The 6-year LFS and OS were 76.4\% and 82.1\%, respectively, in patients who received a high dose of donor CD3+ T cells, which were significantly higher than the LFS and OS in patients who received a lower dose of donor CD3+ T cells (49.5\% and 55.3\%, URL No GVHD was observed in any of the URL
Clinical Studies In a randomized controlled trial from 2004 to 2009, 58 AML patients aged 60–88 years were randomly assigned to receive chemotherapy (control group; n=28) or it plus HLA-mismatched G-CSF–mobilized donor peripheral blood stem cell (G-PBSC) (G-PBSC group/ Microtransplantation; n = 30). The complete remission rate was significantly higher in the G-PBSC group than in the control group (80.0\% vs 42.8\%); The median recovery times of neutrophils and platelets were 11 days and 14.5 days, respectively, in the G-PBSC group and 16 days and 20 days, respectively, in the control group after chemotherapy; The 2-year probability of disease-free survival (DFS) was significantly higher in the G-PBSC group than in the control group (38.9\% vs 10.0\%). No graft-versus-host disease was observed in any patient. Persistent donor microchimerism was successfully detected in all of the 4 female patients. In another long-term research from 2004-2011, 101 patients with AML-CR1 (9 to 65 years old) received Microtransplantation regimen. The 6-year leukemia-free survival (LFS) and overall survival (OS) rates were 84.4\% and 89.5\%, respectively, in the low-risk group, which were similar to the rates in the intermediate-risk group (59.2\% and 65.2\%, respectively); The 6-year LFS and OS were 76.4\% and 82.1\%, respectively, in patients who received a high dose of donor CD3+ T cells, which were significantly higher than the LFS and OS in patients who received a lower dose of donor CD3+ T cells (49.5\% and 55.3\%, respectively). No GVHD was observed in any of the patients.
R
URL
10.0\%).
R
URL
patient.
R
URL
patients.
R
URL
respectively).
R
URL
patients.